$CGEN
HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology Symposium, taking place February 28-March 2, 2019, in San Francisco, CA
September 30, 2018
------------------------
Total current assets - 44,490K$
Net loss for 3M - 3,111K$
A low risk for Offering before ASCO-SITC Clinical Immuno-Oncology Symposium.
------------------------
Technically
--------------
support at 3.29 (Possibility for a bullish flag pattern)
In today Avg 3.41 (Second cycle)
Not for any suggestion - very risky.
September 30, 2018
------------------------
Total current assets - 44,490K$
Net loss for 3M - 3,111K$
A low risk for Offering before ASCO-SITC Clinical Immuno-Oncology Symposium.
------------------------
Technically
--------------
support at 3.29 (Possibility for a bullish flag pattern)
In today Avg 3.41 (Second cycle)
Not for any suggestion - very risky.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.